Cancer in New Zealand

IARC estimates 28,738 new cancer cases and 11,842 cancer deaths in New Zealand in 2024; the commonest new cancers are breast, prostate and colorectum. This page is assembled automatically from OnCo's data: 231 trials with a site there, 4 institutions, 2 companies and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

28,738

all cancers

Deaths

11,842

all cancers

Incidence rate

294.4

per 100,000, age-standardised

Mortality rate

97.6

per 100,000, age-standardised

Cumulative risk

28.6%

of a cancer by age 74

Population

5,213,949

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	4,090	95.0	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	4,012	82.8	Prostate cancer
Colorectum	3,962	36.1	Colorectal cancer
Trachea, bronchus and lung	2,865	25.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Melanoma of skin	2,847	29.2	Melanoma
Non-Hodgkin lymphoma	1,142	11.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Leukaemia	849	9.7	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Pancreas	779	6.8	Pancreatic ductal adenocarcinoma
Kidney	690	7.6	Renal cell carcinoma
Corpus uteri	682	14.8	Endometrial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	2,298	19.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,711	13.0	Colorectal cancer
Prostate	870	11.9	Prostate cancer
Breast	801	15.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	676	5.7	Pancreatic ductal adenocarcinoma
Non-Hodgkin lymphoma	426	3.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Leukaemia	422	3.5	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Melanoma of skin	403	3.2	Melanoma
Liver and intrahepatic bile ducts	375	3.5	Hepatocellular carcinoma
Stomach	333	3.0	Gastric & gastro-oesophageal junction cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “New Zealand”, in Australia/New Zealand (Oceania), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

231 trials in OnCo · 55 recruiting overall

231 trials

Trial			Lead sponsor
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781	Phase 3	Recruiting	Verastem, Inc.	106	2026-10-07
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	82	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164	Phase 3	Recruiting	Merck Sharp & Dohme LLC	54	2026-10-06
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939	Phase 2/3	Recruiting	Hoffmann-La Roche	206	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	77	2026-10-06
waveLINE-003 NCT05139017	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	135	2026-10-06
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851	Phase 3	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-05
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
FORTIFI-HN01 NCT06788990	Phase 2/3	Recruiting	Bicara Therapeutics	231	2026-10-02
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654	Phase 3	Recruiting	Boehringer Ingelheim	167	2026-09-29
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT07011719	Phase 3	Recruiting	Arcus Biosciences, Inc.	183	2026-09-29
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784	Phase 3	Recruiting	Revolution Medicines, Inc.	158	2026-09-29
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) NCT06961006	Phase 2	Recruiting	Merck Sharp & Dohme LLC	38	2026-09-28
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862	Phase 3	Recruiting	Hoffmann-La Roche	210	2026-09-28
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187	Phase 3	Recruiting	BeOne Medicines	217	2026-09-28
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872	Phase 3	Recruiting	BeOne Medicines	195	2026-09-28
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia NCT07277231	Phase 3	Recruiting	BeOne Medicines	115	2026-09-28
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac NCT06742996	Phase 3	Recruiting	BeOne Medicines	150	2026-09-28
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm NCT06312137	Phase 3	Recruiting	Merck Sharp & Dohme LLC	270	2026-09-25

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in New Zealand, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in New Zealand is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

4 institutions

Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service Cancer Society of New Zealand Psychosocial Oncology New Zealand Starship Blood and Cancer Centre

2 companies

Pacific Edge Volpara Health

1 person

People whose main affiliation in OnCo is an institution or company in New Zealand.

Dale Bramley

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. New Zealand is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read New Zealand's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in New Zealand, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from New Zealand's own sources.

New Zealand is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/nz.json; every country: /api/v1/countries.json.